Integer Holdings Corp (ITGR) · Oct 14, 2026 · Acquisition
Proxy supplement — 3 lawsuits, 13 demand letters; stockholder vote October 21
Integer’s acquisition proxy supplement adds disclosure around three lawsuits and 13 demand letters, but leaves the $127-per-share KKR deal intact.
Integer is a medical-device contract development and manufacturing company serving cardiac rhythm management, neuromodulation, and cardio-vascular markets; it is now navigating a pending $5.7 billion all-cash KKR acquisition rather than executing as a standalone public company.
The filing is procedural, but it raises execution risk. Three shareholder lawsuits allege that the merger proxy omitted or misleadingly described material information and seek to block the transaction. 〔0〕 Thirteen additional purported shareholders have sent demand letters making similar disclosure claims. 〔1〕
Integer is trying to clear the litigation hurdle without changing the deal. The company says the claims lack merit, but is voluntarily supplementing the proxy to reduce the cost and uncertainty of defending the cases. 〔2〕 There is no revised purchase price, new bidder, or change to the scheduled October 21 stockholder vote in this filing.
The added sale-process detail supports the board’s process defense, not a higher transaction value. Integer says Goldman Sachs contacted more than 20 potential counterparties, signed confidentiality agreements with 20 parties, and provided diligence materials to each. 〔3〕 The supplemental valuation disclosure also shows Goldman’s illustrative per-share range of $98.93 to $140.68, compared with KKR’s agreed $127 offer; that helps explain why the board considered the deal defensible, but does not alter the economics shareholders are being asked to approve.
Bottom line: This is a merger-process cleanup, not a change to the KKR transaction. It modestly complicates closing by formalizing injunction and disclosure risk, while the deal terms and October 21 vote remain unchanged.
Stockholder vote on the KKR merger, October 21
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!